Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Radiation. University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States

Survival: 16.3 months
Toxicity Grade: 5
Treatments: Chemotherapy
Drugs: Paraplatin
Country: United States
City/State/Province: Pittsburgh, PA
Hospital: University of Pittsburgh Cancer Institute
Journal: Link
Date: 9/2005

Patients: This Phase II/III study involved 276 patients with advanced non-small-cell lung cancer who were randomly assigned into three groups. Group C had 92 patients (62 men, 30 women); twenty-three were over 70 years old.

Treatment: The treatment consisted of radiotherapy and two chemotherapeutic agents: carboplatin and paclitaxel. Group C received both chemotherapy and radiotherapy followed by chemotherapy.

Toxicity: There were two treatment related deaths in this group from infection. Other grade 3-4 toxicities included leukopenia, esophagitis, granulocytopenia, lung, thrombocytopenia, neurologic, anemia, hyperglycemia, cardiac, and nausea/vomiting. There were significantly more patients with adverse effects in Group C than those in other two groups.

Results: The median overall survival was 16.3 months. The authors concluded, "Concurrent weekly paclitaxel, carboplatin, and [thoracic radiotherapy] followed by consolidation seems to be associated with the best outcome, although this schedule was associated with greater toxicity."

Support: Bristol Meyers Squibb financially supported this study, and several authors have disclosed financial relationships with Bristol Meyers Squibb. Bristol Meyers Squibb manufactures and/or markets paclitaxel and carboplatin.

Correspondence: Chandra P. Belani, MD

E-mail to a Friend Email Physician More Information